US FDA orders new eye risk warnings for Ozempic, Zepbound | CNN
cnn1 min read1 reads
The US Food and Drug Administration on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
The FDA said it is requiring GLP-1 drugs to add information warning about rare risk of vision loss.
Jaap Arriens/NurPhoto/Shutterstock
See all topics
Email
Link Copied!
Reuters —
The US Food and Drug Administration on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
The FDA said it is requiring GLP-1 drugs such as Eli Lilly’s Mounjaro and Zepbound, and Novo Nordisk’s Ozempic and Wegovy to add information to the “warnings and precautions” section of labeling about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
